Wellington Management Group LLP Lowers Stock Position in Edwards Lifesciences Corporation $EW

Wellington Management Group LLP lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 23.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,827,967 shares of the medical research company’s stock after selling 5,183,134 shares during the quarter. Wellington Management Group LLP owned approximately 2.92% of Edwards Lifesciences worth $1,522,258,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $26,000. TrinityBridge Ltd purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $27,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter worth about $26,000. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the 1st quarter worth about $25,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences during the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 4,501 shares of company stock worth $408,213 in the last 90 days. 0.31% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EW. BTIG Research boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Truist Financial lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Piper Sandler reissued an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. UBS Group initiated coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target for the company. Finally, Citigroup upped their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Price Performance

NYSE:EW opened at $90.19 on Friday. The stock has a 50 day moving average of $89.54 and a two-hundred day moving average of $85.03. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The firm has a market cap of $51.93 billion, a P/E ratio of 51.83, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.